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Background: The use of artificial colloids is currently controversial, especially in Central Europe Several studies
demonstrated a worse outcome in intensive care unit patients with the use of hydroxyethyl starch. This recently
even led to a drug warning about use of hydroxyethyl starch products in patients admitted to the intensive care
unit. The data on hydroxyethyl starch in non–critically ill patients are insufficient to support perioperative use.
Methods/Design: We are conducting a single-center, open-label, randomized, comparative trial with two parallel
patient groups to compare human albumin 5 % (test drug) with hydroxyethyl starch 6 % 130/0.4 (comparator). The
primary endpoint is cystatin C ratio, calculated as the ratio of the cystatin value at day 90 after surgery relative to
the preoperative value. Secondary objectives are inter alia the evaluation of the influence of human albumin and
hydroxyethyl starch on further laboratory chemical and clinical parameters, glycocalyx shedding, intensive care unit
and hospital stay and acute kidney injury as defined by RIFLE criteria (risk of renal dysfunction, injury to the kidney,
failure of kidney function, loss of kidney function, and end-stage kidney disease) criteria.
Discussion: There is a general lack of evidence on the relative safety and effects of hydroxyethyl starch compared
with human albumin for volume replacement in a perioperative setting. Previously conducted studies of surgical
patients in which researchers have compared different hydroxyethyl starch products included too few patients to
properly evaluate clinical important outcomes such as renal function. In the present study in a high-risk patient
population undergoing a major surgical intervention, we will determine if perioperative fluid replacement with
human albumin 5 % will have a long-term advantage over a third-generation hydroxyethyl starch 130/0.4 on the
progression of renal dysfunction until 90 days after surgery.
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Various crystalloid and colloid solutions are available
to the clinician for perioperative volume replacement
therapy. Colloids are large–molecular weight (nomin-
ally MW >30,000) substances. In normal plasma, the
plasma proteins are the major colloids present. Albu-
min solutions are available for use as colloids. Various
other solutions containing artificial colloids, such as
hydroxyethyl starches (HESs), are commonly used in
clinical praxis.
Different preparations are indicated according to the dif-
ferent patient types and the type of fluid loss. For some
decades there have been contradicting philosophies, in
particular concerning the best choice for volume substi-
tutes to deal with perioperative blood loss. However, fluid
preloading and liberal intraoperative fluid substitution are
not evidence-based procedures [1]. According to current
reviews, recommended rational fluid therapy includes a
combination of crystalloid and colloid solutions. An ad-
equate replacement of fluid needs seems to have the
power to improve patient outcomes and should be consid-
ered the therapy of choice to minimize perioperative fluid
shifting [2].
HES solutions are used for the treatment of hypovol-
emia (low blood volume) when plasma volume expansion
is desired. There is conflicting evidence about its relative
safety, most notably regarding adverse effects of HES on
kidney function.
In an animal model, the application of 10 % HES 200,000
already led to a reduction of diuresis and increases in in-
flammation and tubular damage [3]. These effects were
more distinctive in 10 % HES 200,000 than in 6 % HES
130,000 or lactated Ringer solution.
In the Efficacy of Volume Substitution and Insulin
Therapy in Severe Sepsis study, conducted by the
German Competence Network Sepsis, the authors
compared 10 % HES 200,000 with lactated Ringer
solution as volume replacement therapy in critically
ill patients. In the HES group, the incidence of
acute renal failure, renal replacement therapy and
need for blood transfusion were significantly in-
creased. The authors postulated that the long stor-
age of HES molecules in the tissue and a potential
direct toxicity of the substance per se could be re-
sponsible for these negative effects [4]. Indeed, these
results were seen only in patients who received
more than 22 ml/kg/day.
Schabinski and colleagues compared the effect of
6 % HES 130/0.4 with 4 % gelatin on renal failure
and mortality in critically ill surgical patients. They
showed that a significant increase in mortality and
acute renal failure occurred in the HES group if the
cumulative dose of 33 ml/kg body weight was
exceeded [5].A survey of 120 Scandinavian intensive care units
(ICUs) published in 2008 [6] revealed that, for most
physicians, colloids are a second-choice volume
substitute. Only one-third were found to use it as a
primary volume substitute. HES 130/0.4 was the
preferred colloid. A large part of the interviewees
attested that there were no internal directives or
contraindications for the use of HES at their centers.
At the same time, almost all interviewees indicated
that they would change their infusion practice if ran-
domized controlled studies clearly showed negative
effects on mortality and renal failure [6].
An alternative to HES is the use of human albu-
min (HA). The safety of HA was examined in the
Saline versus Albumin Fluid Evaluation (SAFE)
study, published in 2004 [7]. In that large investiga-
tion, the impact of saline 0.9 % and albumin 4 %
was compared in critically ill patients. Neither in the
whole group nor in one of the subgroups was a
relevant difference found with regard to mortality,
ICU length of stay, organ failure, respiratory support
or renal replacement therapy. A post hoc analysis
showed that the results were independent of the
serum albumin value of the patients [8]. Indeed, in a
subgroup analysis, the authors found an increase in
mortality in patients with brain injury who received
albumin compared with those in the saline group
[9]. However, this was not a negative effect of the
colloid albumin, but the result of volume loading in
patients who are not hypovolemic and therefore
without demand of any colloid infusion [10].
In a meta-analysis, Wilkes and Navickis investi-
gated the safety of albumin and its influence on
mortality. The authors compared 55 randomized tri-
als in patients after major surgery, trauma, burn,
hypoalbuminemia, ascites and other diseases. The re-
searchers in the included trials compared albumin
therapy with crystalloid therapy, no albumin or
lower doses of albumin. Overall, the authors found
no effect of albumin on mortality [11].
In an experimental study, Jacob et al. [12] investi-
gated the different negative effects of colloids on
vascular permeability. The authors perfused an iso-
lated heart (guinea pig) with 5 % albumin, 6 % HES
130/0.4 and saline 0.9 % and observed the fluid ex-
travasation before and after 20 minutes of ischemia.
This study demonstrated a significantly lower ex-
travasation in the albumin and HES group compared
with the group that was given saline 0.9 %. After is-
chemia, a transient increase in vascular permeability
resulted from use of HES and saline 0.9 %. In the
albumin group, there was no increase in vascular
leakage. This effect was independent of the intravascu-
lar colloid osmotic pressure. The authors concluded
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which seems to be the cause of the protective effects of
albumin on the vascular barrier [12].
In an investigation on isolated heart perfusion, Jacob
et al. [13] examined the effects of albumin on endothelial
integrity and myocardial function after 4 h of ischemia.
The authors compared Bretschneider solution with and
without addition of albumin. After reperfusion, intra-
coronary adhesion of polymorphonuclear granulocytes,
edema formation, left and right heart performance of
pressure-to-volume work, and glycocalyx formation were
assessed. The intracoronary adhesion of leukocytes was
doubled in the Bretschneider solution group, whereas
it remained at basal values after albumin addition.
Addition of albumin also decreased edema and led to
significantly better right ventricular function. Glycoca-
lyx shedding was significantly lower in the albumin group
than in the group without albumin addition. The authors
concluded that addition of albumin improves endothelial
integrity as well as heart function after 4-h ischemia,
owing to protection of the glycocalyx [13].
The effects of HES 200/0.6 and HES 130/0.4 on renal
function after transplant were compared in a retrospective
investigation by Blasco et al. in brain-dead donors [14].
Thirty-two donors were included in every group. The
appearance of delayed organ function and postsurgical
creatinine was documented. Delayed organ function
was found in the group treated with HES 130/0.4 com-
pared with patients treated with HES 200/0.6. The cre-
atinine levels after 1 month amounted to 133 μmol/L
in the HES 130/0.4 group and 172 μmol/L in the HES 200/
0.6 group (p = 0.005). After 1 year, increased creatinine was
found in the HES 200/0.6 group compared with the HES
130/0.4 group (147 μmol/L versus 128 μmol/L; p = 0.05).
The authors concluded that the use of modern third-
generation HES preparations are associated with better
postsurgical renal function [14].
Van der Linden et al. compared HES 130/0.4 with modi-
fied 3 % gelatin solution in 132 cardiac surgery patients with
regard to perioperative blood loss and transfusion need.
Both groups also received a cumulative dose of 48.9 ml/kg
of colloids. Blood loss, transfusion need, laboratory parame-
ters and hemodynamics were comparable in both groups.
The authors concluded that it is safe to use 50 ml/kg of
HES 130/0.4 [15].
In a systematic review, Hartog and colleagues [16] identi-
fied 56 randomized controlled trials on the use of HES
130/04 in an elective surgical setting. These studies were
small-sized and of short duration. The main goal was to as-
sess whether published studies on HES 130/0.4 resuscita-
tion are sufficiently well designed to make conclusions
about the safety of this compound. The 56 studies were
small, heterogeneous, and involved different control fluids
and different clinical conditions. The authors concludedthat the results of these studies could not be pooled and
that the studies did not provide convincing evidence that
third-generation HES 130/0.4 is safe in surgical, emer-
gency, or ICU patients, despite publication of numerous
clinical studies [16].
Recent data have associated the use of HES products with
an increased risk of severe adverse events (SAEs) when used
in certain patient populations. After a review of the available
evidence [17], on 14 June 2013, the Pharmacovigilance Risk
Assessment Committee of the European Medicines Agency
concluded that the benefits of HES solutions no longer out-
weighed their risks and recommended that the marketing
authorizations for these medicines be withdrawn [18]. The
European Union regulatory agency then decided to restrict
the indication for HES solutions. HES is now indicated only
as second-line treatment after crystalloids when there is
acute bleeding. The use of HES solution is contraindicated
in critically ill patients, including those with sepsis, burns,
transplant and cerebral bleeding, and renal impairment
and/or hepatic dysfunction. On 24 June 2013, the U.S.
Food and Drug Administration recommended that HES
products not be used in critically ill patients or in those
with preexisting renal dysfunction, but it also did not
withdraw them completely.
Despite of the fact that there are several small clinical
trials in which HES was compared with another fluid for
volume replacement in various clinical settings, there is a
general lack of evidence on the relative safety and efficacy
of HES versus HA for volume replacement in the peri-
operative period. Previously conducted studies of surgical
patients in which different HES products were compared
included too few patients for proper evaluation of import-
ant clinical outcomes, such as renal function.
In the present study, we will determine, in a patient popu-
lation undergoing a major surgical intervention, if periopera-
tive fluid replacement with HA has a long-term advantage
compared with a third-generation HES (HES 130/0.4) on
the progression to renal dysfunction until 3 months after
surgery.Hydroxyethyl starch 6 % 130/0.4 (Volulyte)
Blood and protein losses that occur during surgical
procedures can be compensated by the patients up to a
certain point. The current infusion practice is to pro-
vide a combination of crystalloid and colloid solutions.
The objective is to reach hemodynamic targets and
treat the diuresis of the patient to maintain sufficient
organ perfusion. Guided by the hemoglobin values,
blood transfusions are also used.
Protein and blood losses are currently substituted, at
least in Central Europe, with HES. The common modern
preparation is 6 % HES with a MW of 130 kDa and a
substitution degree of 0.4 (Volulyte; Fresenius Kabi, Bad
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parison with the serum value, higher sodium and chlor-
ide amounts (154 mmol/L in each case). According to
the manufacturer, the maximum dose to be adminis-
tered is 50 ml of hydroxyethyl starch/kg (i.e., 3500 ml
for a patient of 70-kg body weight). This dose is based
on experimental investigations in rats where the infu-
sion of 9 g/kg HES showed no toxic effects. Information
concerning the maximum dose to be administered in
humans is absent.
Up to now, HES preparations of the modern gener-
ation were examined only in specified patient groups.
No publication of a systematic investigation with in-
formation about maximum administrable dose exists in
the literature. Therefore, it is unclear whether organ-toxic
or coagulation-restraining effects, as proved with older HES
preparations, also occur with use of the modern products.
Human albumin 5 % (Humanalbin)
HA is a natural component of blood plasma and is
responsible for colloid osmotic pressure. It has a
MW of 66 kDa and acts as a transport protein for
water-indissoluble substances in the blood. It binds
cations as well as anions and contributes on account
of these ampholytic qualities to the buffer capacity.
In addition, it is an important component of the
endothelial glycocalyx, which forms the so-called
endothelial surface layer, together with the endothe-
lial cell line.
HA as a colloidal volume substitute is a content of vari-
ous clinical and experimental investigations. Still, there is
controversial international discussion regarding this sub-
stance as infusion solution. The SAFE study investigators
examined this aspect in the most recent study. Indeed,
those authors compared HA with a crystalloid solution (sa-
line 0.9 %). The safety of this substance could be proved in
the whole group, even though a subgroup showed conflict-
ing results [9].
The HA solution used in this investigation is a 5 %
infusion solution (Humanalbin; CSL Behring, Marburg,
Germany) with at least 96 % HA. The substance is licensed
for volume replacement therapy. Dosage and infusion rate
are recommended to be adjusted to the patient’s individual
requirements. There is no upper dose limit.
Trial rationale
In the present trial, data concerning postoperative renal
function are the main interest, in addition to blood loss,
need for transfusions and coagulation substitutes, hospital
stay, and complications and mortality. Patients undergoing
cystectomy will be included. These patients are considered
high-risk patients for the development of progressive renal
dysfunction postoperatively based on their underlying dis-
ease and the severe surgical intervention. Because of itshigher accuracy, cystatin C was chosen for calculation of
glomerular filtration rate (GFR) [19, 20].
Both colloid solutions, HES and HA, are used in routine
clinical perioperative settings. Their comparative safety
and long-term effects on renal function in perioperative
patients has not been studied in well-controlled and ad-
equately powered randomized clinical trials. It is expected
that the findings of this trial will increase knowledge about
fluid management in surgical patients who are at risk for
developing renal dysfunction postoperatively.
Trial objectives and endpoints
Primary objective
Our primary objective is to compare the effects on
renal function of HA 5 % with those of HES 130/0.4
when administered for perioperative volume replace-
ment in patients undergoing cystectomy, with the aim
of demonstrating the superiority of HA over HES.
Primary endpoint
The primary endpoint is the cystatin C ratio, calculated
as the ratio of the cystatin value at day 90 after surgery
relative to the preoperative value. This ratio corre-
sponds to the calculated GFR ratio (the value at day 90
relative to that before surgery). The calculation of the
GFR is carried out with the help of cystatin C, based
on the following formula:
GFR ml=minð Þcalculated ¼ 74; 835  cystatin C mg=Lð Þ−1333
Secondary objectives
Secondary objectives of the clinical investigation are
the evaluation of the influence of HA and HES on fur-
ther laboratory chemical and clinical parameters, ICU
and hospital length of stay and acute kidney injury as
defined by RIFLE criteria (risk of renal dysfunction, in-
jury to the kidney, failure of kidney function, loss of
kidney function, and end-stage kidney disease). Also,
we are interested in the presence of pruritus evaluated
by conducting a standardized interview.Secondary endpoints
 Incidence of acute kidney injury as defined by RIFLE
criteria (in hospital and at midterm [3 months])
(see Appendix: Table 4)
 Relative change of calculated GFR (by cystatin C) up
to the third postoperative day
 Glycocalyx shedding (syndecan 1, hyaluronan) at
days 0, 1 and 3
 Glomerular damage as measured by neutrophil
gelatinase-associated lipocalin at days 0, 1, 3 and 90
 Length of ICU and hospital stay
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Further objectives and variables
We also want to investigate the effect of the fluid
therapy on the thrombocyte function and coagulation
as measured using the Multiple Platelet Function
Analyzer (Multiplate; Roche Diagnostics, Mannheim,
Germany), Platelet Function Analyzer (PFA 100; Siemens
Healthcare, Erlangen, Germany) and rotational thrombe-
lastometry (ROTEM; Tem international GmbH, Munich,
Germany). Also we are interested in the life quality after
the operation evaluated by standardized interviews. Fur-
thermore, we will collect the following data:
 Intraoperative blood loss, urine output and fluid
amount
 The laboratory chemical course of creatinine and
urea, starting before surgery up to the third
postoperative day and at 90 days (visit 5)
 The laboratory chemical course of serum albumin,
starting presurgically up to the third postoperative day
 Mortality
 Dementia screening (Mini Mental State Examination)
on the day of screening
 Delirium screening (Nursing Delirium Screening
Scale) postoperatively in the recovery room and at
days 1 and 3
 Life quality assessment preoperatively and at day 90
(activities of daily living, instrumental activities of
daily living)
 Effect on thrombocytes and coagulation measured
by ROTEM, PFA 100) and Multiplate at day 0
 Incidence of adverse events and SAEs
Methods/Design
In this single-center, open-label, randomized, comparative
trial, we will investigate two parallel patient groups, com-
paring HA (test drug) versus HES (comparator). Ethical ap-
proval of this trial was obtained from the ethics committee
of the Ludwig Maximilians University of Munich (reference
number 311-11). The confirmatory statistical analysis is
based on a leading surrogate parameter of renal function,
with the aim of establishing a recommendation for therapy
optimization. Because both investigational medicinal prod-
ucts (IMPs) are licensed for volume replacement in the
perioperative setting in this trial, it is a phase IV trial. How-
ever, the clinical aim corresponds to that of a confirmatory
phase IIb or III trial.
Randomization will be performed by stratifying partici-
pants by type of surgical procedure (ileum conduit or
neobladder) to balance allocation to treatment groups
with respect to this risk factor for postoperative renal
dysfunction.After randomization, each patient will receive the allo-
cated volume replacement treatment according to the
current prescribing information up to the seventh opera-
tive day. The patient should be kept on the allocated in-
fusion solution during the first 90 days after operation if
further volume replacement therapy becomes necessary,
if not contraindicated, and if manageable.
A detailed schedule of study activities, and the treat-
ment algorithm to be used for fluid management in both
treatment arms are provided in the Appendix: Tables 1,
2 and 3.
Anesthetic management
All patients will receive thoracic epidural anesthesia in
combination with general anesthesia before surgery. Pa-
tients with contraindications to neuraxial procedures (e.g.,
dual platelet inhibition) will receive general anesthesia and
postoperative patient-controlled analgesia with piritra-
mide. The anesthetic technique used will be standardized.
Anesthesia will be induced with propofol (2 mg/kg),
sufentanil (0.4 mg/kg) and rocuronium (0.6 mg/kg) and
maintained with propofol and remifentanil or sevoflurane
in patients with certain conditions (e.g., cardiopulmonary
diseases). After surgery, the epidural will be maintained
for at least 3 days and will be combined with acetamino-
phen, non-steroidal anti-inflammatory drug and an opioid
(piritramide) if needed. Intraoperative hemodynamic
monitoring will be performed with a Vigileo monitor with
FloTrac sensor (Edwards Lifesciences, Irvine, CA, USA).
After randomization, patients will receive either HA or
HES from one of the investigators according to an algo-
rithm (see Appendix).
Postoperative care
American Society of Anesthesiologists Physical Status
(ASA) classification I and II patients without cardio-
pulmonary diseases or cerebral insufficiency will be
transferred directly from the recovery room to the
general ward. ASA classifications III and IV patients or
those with perioperative complications will be trans-
ferred from the operating room to the ICU for at least
1 day. All patients will receive early postoperative
enteral feeding without a nasogastric tube as well as
early mobilization. All patients will be visited by in-
hospital postoperative pain management service staff
daily.
Treatment groups
After screening and randomization, every patient is
assigned to one of the two therapy arms:
1. VoluCyst study arm (patients with cystectomy
treated with HES): In this arm, patients receive 6 %
HES 130/0.6 (Volulyte) perioperatively and up to
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according to a treatment algorithm (see Appendix).
The maximum dose according to the prescribing
information is 50 ml/kg/day (e.g., 3500 ml for a
patient with a body weight of 70 kg). Patients who
require additional volume replacement therapy from
day 3 until discharge will be treated primarily with
HES, unless a contraindication to HES has emerged.
2. AlbuCyst study arm (patients with cystectomy
treated with HA): In this arm, patients receive
5 % HA (Humanalbin) perioperatively and up
to the third postoperative day as the only
colloid according to a treatment algorithm
(see Appendix). Patients who require additional
volume replacement therapy from day 3 until
discharge will be treated with HA.
Trial population and selection criteria
Patients will be screened for eligibility by using the surgery
schedule. Patients who seem to be eligible for study par-
ticipation based on their diagnosis are screened according
to the inclusion and exclusion criteria. Patients who fulfill
these criteria are informed about the present study.
Inclusion criteria
Subjects must meet all of the following inclusion criteria
to be eligible for enrolment into the trial:
 Patients (male and female) aged 18–85 years
 Patients undergoing cystectomy with urinary diversion
using an ileal conduit or neobladder procedure
 Ability to follow study instructions and likely to
attend and complete all required visits
 Written informed consent provided
Exclusion criteria
Subjects presenting with any of the following exclusion
criteria may not be included in the trial.
General exclusion criteria
 Unfavorable prognosis (e.g., palliative surgical care
in cases of obstruction of the efferent urinary tract)
 Evidence of metastatic disease
 Bleeding tendency or platelet dysfunction
 Preoperative creatinine clearance <30 ml/min
 Preoperative chemotherapy with nephrotoxic drugs
(e.g., cisplatin)
 Application of >1000 ml of colloid solution within
the 24 h before surgical intervention
 Physical or acute medical condition, psychiatric
condition or laboratory abnormality that, based on
the investigator’s decision, may put the patient at risk,
may confound the trial results or may interfere with
the patient’s participation in this clinical trial History of hypersensitivity to the investigational
drug or to drugs with a similar chemical structure
 History of uncontrolled chronic disease or a
concurrent clinically significant illness or medical
condition that, in the investigator’s opinion, would
contraindicate study participation or compliance
with protocol-mandated procedures
 Known or persistent abuse of medications, drugs or
alcohol
 Simultaneous participation in another clinical trial
or participation in any clinical trial involving an IMP
within 30 days before provision of written informed
consent for this trial
Special restrictions for women
 Current or planned pregnancy or nursing women
 Women of childbearing potential who are not using
and not willing to use medically reliable methods of
contraception for the entire study duration (such as
oral, injectable or implantable contraceptives or
intrauterine contraceptive devices), unless they are
surgically sterilized and/or hysterectomized or there
are any other criteria considered sufficiently reliable
by the investigator in individual cases
Subject information and recruitment
If a patient appears to be eligible for the study, either
the investigator responsible for that site or delegated
medical doctors will provide the patient a full verbal
explanation of the trial and the Patient Information
Sheet so that the patient can consider participating.
This will include detailed information about the ra-
tionale, design and personal implications of the study.
After information is provided to patients, they will
have sufficient time to consider participation before
they are asked whether they would be willing to take
part in the trial.
It is imperative that written consent be obtained be-
fore any trial-specific procedures commence. The inves-
tigator will then record the details of these trial patients
in trial-specific lists.
Randomization and stratification
This trial is designed as an open-label trial. Rando-
mization will be performed at the Institute for Medical
Informatics, Biometry and Epidemiology (IBE) of the
University of Munich, and the treating physicians will be
informed about the treatment arm to which a patient is
assigned.
Randomization to both treatment arms will be per-
formed in a ratio of 1:1. The randomization technique is
based on randomized, balanced blocks with random
block length. The procedure considers stratification by
type of surgical procedure (ileal conduit or neobladder).
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tool (Randoulette), which chooses the colloid treatment
group for a new patient fulfilling the eligibility criteria
and having signed the informed consent. Randoulette
will register the patient by the patient’s pseudonym or
screening number, sex, year of birth and stratum (ileal
conduit or neobladder) before the allocated colloid treat-
ment group is provided.
Statistical planning and analysis
Statistical analyses
The primary efficacy analysis statistically tests super-
iority of HA versus HES at an α significance level of
5 % (two-sided, simultaneously testing both sides at
a level of 2.5 %) with respect to the primary
endpoint.
The primary endpoint is expected to be non-normally
distributed. After logarithm transformation, the primary
endpoint may not be normally distributed. Thus, the
corresponding statistical null hypothesis is the hypoth-
esis that the distribution functions of the endpoint in the
HA group and the HES group are equal and will be
tested non-parametrically with the Mann-Whitney-
Wilcoxon test to detect directed differences of the distri-
butions. The Mann-Whitney-Wilcoxon test will be ap-
plied. The one-sided p value will be calculated, if
possible, using Fisher’s exact test.
The primary endpoint adjusts in a specific way for the
preoperative cystatin C values. At the planning stage, the
Mann-Whitney-Wilcoxon test will be applied in the strati-
fied version by type of surgical procedure (ileal conduit or
neobladder). If adjustments of stratification are deemed
necessary during the course of the trial, the trial protocol
will be amended.
A fixed-sample design is planned. Changes of trial
design, if necessary or advisable, resulting from an interim
analysis without significance testing (no αspent) had to
keep the prespecified significance level. In that case, the
Brownian motion will be used for modeling the primary
test statistic based on the accumulating data as a stochas-
tic process (see next section).
The distributions will be described at all time points by
median, minimum, maximum and quartiles separately for
both the HES and HA groups.
The primary statistical analysis will be based on the
intention-to-treat (ITT) principle.
Analysis of all secondary endpoints and of patient
characteristics will be descriptive. Descriptive compari-
sons will be conducted with the t test or, in the case of
deviations from the normal distribution, with the Mann-
Whitney-Wilcoxon test, or with Fisher’s exact test in
case of a binary outcome.
Safety data will be analyzed descriptively in the two
groups at least every 12 months.Interim analyses regarding confirmatory analysis
An interim analysis will be performed as approximately
a midcourse analysis with the objective of checking the
assumptions of the initial sample size calculation. There
is no α spending prespecified at the planned interim
analysis. In cases where the interim analysis results in
substantial differences from the assumptions at the plan-
ning stage, the assumptions will be revised and a sample
size recalculation will be performed. The sample size re-
calculation will be based on the conditional rejection
probability approach (see next section). If a sample size
modification deems advisable, the study protocol will be
amended.
Calculations for sequential analyses regarding the pri-
mary confirmatory analysis will be done in the Brownian
motion model. Values of a Brownian motion are ap-
proximately resembled based on the accumulating data
and applying the inverse normal transformation of the
(exact) one-sided p values at interim and final analyses
followed by multiplication with the square root of the
information time. The information time is approxi-
mated by
nIC;HA;I⋅nIC;HES;I
nIC;HA;I þ nIC;HES;I þ 1þ
nNB;HA;I⋅nNB;HES;I
nNB;HA;I þ nNB;HES;I þ 1
where nS,T,I denotes the number of patients with
assessed primary endpoint in stratum S (S = IC for ileal
conduit or S = NB for neobladder) and treatment group
T (T =HA or T =HES) at an arbitrary time during the
course of the trial. Alternatively, a proportional informa-
tion time scale may be used (e.g., by multiplication by a
factor of 4).
Modifications of the statistical design for confirmatory
analysis
To keep the type I error level in the case of a design
modification at any time during the course of the trial,
the Conditional Rejection Probability approach of Müller
and Schäfer will be applied [21, 22]. Thereby, as de-
scribed in the preceding section, the calculations will be
based on the Brownian motion approximation. In the
case of a modification of the statistical design (e.g., a
sample size recalculation), the trial protocol will be
amended.
Power considerations and sample size calculation
Three parameters will influence the sample size of the
study, in which we will use the Mann-Whitney-
Wilcoxon test for the statistical decision based on a
fixed-sample design: the level of significance, the power
of the two-sided test and the probability that an observa-
tion XAlbuCyst in the HA group is less than an
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planning, no stratification and approximately normally
distributed data for log-transformed cystatin C values
and calculated log-transformed GFR values are assumed.
The location parameter and standard deviation of cysta-
tin C at baseline are assumed to be 0.9 mg/L and
0.2 mg/L, respectively, based on the publication by
Evangelopoulos and colleagues [23]. Thereby we con-
sider the older patient groups and greater variability be-
cause subgroups are pooled and study patients did not
represent a healthy population.
For sample size calculation, the value of 0.2222 for
the standard deviation of the difference at day 90 minus
baseline of the log-normal transformed cystatin C
values is specified in both treatment groups. There are
two arguments for this specification. First, the value is
suggested to be conservative in the four groups (two
treatments times two measurement time points) con-
sidered in the statistical analyses. Second, adjusting for
baseline values by using cystatin C values at day 90
relative to the same patients’ value at baseline is sug-
gested to reduce rather than to increase the standard
deviation.
An increase of the GFR by the factor 1.2 due to
HA compared with HES would be clinically meaning-
ful and worthwhile to be detected as statistically sig-
nificant difference at a two-sided type I error level of
α = 5 % with a statistical power of 1 − β = 80 %. For
the interpretation of the increase of the GFR by the
factor 1.2 consider, for example, a patient with a
Cystatin C value of 0.9 mg/L. This value results in a
calculated GFR at baseline between 86 and 87 ml/
min. Then, the factor 1.2 would mean an increase of
GFR at day 90 from 60 to 72 ml/min, from 65 to
78 ml/min, or from 70 to 84 ml/min.
The factor of 1.2 with respect to GFR transfers to the
detectable difference of 0.1368 for the log-transformed
(natural logarithm) Cystatin C values when using the
conservative formula where the exponent is −1.333.
The detectable difference and the specified standard
deviation correspond to the probability of
P XAlbuCyst < XVoluCyst
  ¼ 0:6683:
With a sample size of 47 in each group, the non-
stratified Mann-Whitney-Wilcoxon test at a 0.05 two-
sided significance level will have 80 % power to detect a
probability of 0.6683 that an observation XAlbuCyst is
less than an observation XVoluCyst. This means that n = 94
assessed patients are required in total to achieve the
desired power.
On the basis of our experience with patient compli-
ance in previous studies and routine treatment, weexpect a dropout rate of about 10 %. Thus, adjusting
for slight random imbalances in allocation to the treat-
ment groups, a total of 105 patients (50–55 in each
treatment group) have to be enrolled.
It has to be taken into consideration that about 50 % of
patients fulfilling the inclusion criteria for this trial might
refuse to give their informed consent to participate; we
therefore expect to screen a total of about 210 patients for
eligibility.
Sensitivity analyses
After the primary ITT analysis, sensitivity analyses will
follow per protocol or according to as-treated princi-
ples. In addition to the primary Mann-Whitney-
Wilcoxon analysis, the Mann-Whitney-Wilcoxon test
will be applied to the cystatin C values at day 90, and,
assuming approximately normal distributions after log
transformation (natural logarithm), explorative regression
analyses will be performed modeling the log-transformed
(natural logarithm) cystatin C values depending on
treatment group, log-transformed (natural logarithm)
baseline cystatin C values and other potentially prog-
nostic factors.
Ethics and Good Clinical Practice
The trial will be conducted in accordance with the
International Conference on Harmonization guidance
regarding Good Clinical Practice, the relevant national
regulations and the Declaration of Helsinki. The study
protocol and consent forms were approved by the in-
stitutional review board of the Ludwig Maximilians
University of Munich (reference number 311-11).
Discussion
Despite the fact that there are several smaller clinical
trials comparing HES to another fluid for volume re-
placement in various clinical settings, there is a general
lack of evidence on the relative safety and effects of
HES versus HA for volume replacement in a periopera-
tive setting. Previously conducted studies of surgical pa-
tients in which researchers compared different HES
products included too few patients for proper evalu-
ation of clinically important outcomes such as renal
function.
The present study will determine, in a high-risk pa-
tient population undergoing major surgical interven-
tion, whether perioperative fluid replacement with HA
has a long-term advantage over a third-generation
HES (HES 130/0.4) on the progression to renal dys-
function until 3 months after surgery.
Trial status
The study was initiated as planned in May 2012. The
study is expected to be completed in February 2016.
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Schedule of activities Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Screening day (day −1) Day 0 (day of surgery) Day 1 Day 3 Day 90
Informed consent X
Inclusion and exclusion criteria X
Demographic data X
Medical history (primary diagnosis) X
Pregnancy test for women of childbearing potential X
Mini Mental State Examination X
Life Quality Assessment (ADL, IADL) X X
Concomitant medications (diuretics) X X X X X
Cystatin C, GFR, serum creatinine X X X X X
ROTEM, Multiplate, PFA 100 X
Randomization X
NGAL, syndecan 1, hyaluronan X X X
Study drug X X X
Blood products X X X
IV fluid amount X X X
Blood losses and urine output X X X
Nursing Delirium Screening Scale X X X
AEs and SAEs X X X X
Pruritus assessment X
ADL activities of daily living, AE adverse event, IADL instrumental activities of daily living, IV intravenous, NGAL neutrophil gelatinase-associated lipocalin, PFA 100 Platelet
Function Analyzer 100, ROTEM rotational thrombelastometry, SAE serious adverse event2Table 2 Algorithm of infusions and transfusion in the operating room and intensive care unit
Hemodynamics
ASA I and II patients without cardiac diseases or cerebral insufficiency:
Stroke volume variation (SVV) <12 %
Cardiac index (CI) > 2.5 L/min/m2
MAD >60 mmHg




Central venous oxygen saturation >70 % or mixed venous oxygen saturation >65 %
To reach the desired parameter:
Start with infusion protocol (see below)
If not successful within 15 minutes:
Start with norepinephrine as first-choice vasopressor
Infusion protocol
Replacement of urine output with Ringer’s acetate solution in a 1:1 ratio
Additionally, 500 ml of crystalloids for insensible sweating
Replacement of blood and protein losses dependent on treatment assignment, with either HA 5 % or HES 6 % in a 1:1 ratio up to a transfusion trigger
point or a maximum of 50 ml/kg/day
Additionally up to 1500 ml of colloids for the protein loss into the third compartment
Table 3 Transfusion protocol (in support of [24])
Red blood cells
Hb (g/dl) Risk factors Transfusion Evidence
level
<6 g/dl – Yes 1c+




risk factors (cardiac diseases,
cerebrovascular insufficiency)
Yes 1c+
Signs of anemic hypoxia
(tachycardia, hypotension,
lactic acidosis, ECG change)
Yes 1c+
8–10 g/dl Signs of anemic hypoxia
(tachycardia, hypotension,
lactic acidosis, ECG change)
Yes 2c
>10 g/dl – No 1a
ADL activities of daily living, AE adverse event, ECG electrocardiographic,
Hb hemoglobin, IADL instrumental activities of daily living, SAE serious
adverse event
Table 4 RIFLE criteria as defined by Bellomo et al. [25]
Category GFR criteria Urine Output (UO) criteria
Risk Increased creatinine × 1.5 or
GFR decrease > 25 %
UO <0.5 ml/kg/h for 6 h
Injury Increased creatinine × 2 or
GFR decrease > 50 %
UO <0.5 ml/kg/h for 12 h
Failure Increase creatinine × 3 or
GFR decrease > 75 %
UO <0.3 ml/kg/h for 24 h
or anuria for 12 h
Loss Persistent ARF = complete loss of kidney function >4 wk
ESKD End-stage kidney disease (>3 mo)
ARF acute renal failure, ESKD end-stage kidney disease, GFR glomerular filtration
rate, RIFLE risk of renal dysfunction, injury to the kidney, failure of kidney function,
loss of kidney function, and end-stage kidney disease, UO urine output
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